Binding Kinetics Supporting Peptide Discovery
We’ve joined forces with Dr. Michael Goldflam from Pepscan to deliver a webinar full of peptides and kinetic characterization for therapeutic and diagnostics development.
Why this webinar?
CLIPS® meets the WAVE
In this webinar, Dr. Michael Goldflam (Pepscan) will present the CLIPS® discovery pipeline for the development of peptides for therapeutic and diagnostic purposes starting from phage encoded constrained peptide libraries to the optimization of lead compounds. Dr. Fabio Andres (Creoptix), goes deep into the biophysical characterization of molecules using the Creoptix® WAVEsystem for label-free, real-time affinity and kinetics characterization. Discover the benefits of early stage kinetic characterization to complement and validate binding affinity in crude reaction mixtures, biofluids (serum and plasma) and other matrixes.
What can I expect to learn during this webinar?
- Optimization of peptides for therapeutic and diagnostic purposes.
- Off-rate screening as a valuable alternative approach to small molecule fragments and peptide selection in drug discovery.
- GCI technology can be used as orthogonal validation technique for ELISA data.
- Measuring kinetics in biofluids provides valuable insights into a drug’s efficacy.
- CLIPS® as a powerful and bio-orthogonal peptide cross linking chemistry.
- Identification of CLIPS® constrained redox-stable macrocyclic peptides via phage display and NGS analysis.
Application Scientist at Creoptix AG
Fabio Andres, PhD
Dr. Fabio Andres has a strong background in protein biochemistry, cancer drug research and the development of diagnostic assays and biosensor applications. Holding a Ph.D. in Biochemistry from the University of Zurich, he joined Creoptix as an Application Scientist in 2018.
Director of Peptide Discovery at Pepscan
Michael Goldflam, PhD
Dr. Michael Goldflam, investigated during his PhD different means to target protein-protein interactions ranging from fragment-based drug discovery at Prof. Ernest Giralt’s lab at IRB Barcelona to mRNA display at Prof. Hiroaki Suga group at the University of Tokio. The later motivated him to pursue a postdoc in Cambridge where he used cell free display technologies to identify peptides and antibodies for cancer related signalling pathways as part of an academia/industry consortium. In 2016 Michael joined Pepscan where he developed Pepscan’s Peptide Discovery Phage Display platform.